Drug Profile
Hirudin biosimilar - Kerun Biopharmaceutical
Alternative Names: recombinant hirudin - Kerun BiopharmaceuticalLatest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator Kerun Biopharmaceutical
- Class Antithrombins; Hirudins
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 28 May 2019 No recent reports of development identified for phase-I development in Thrombosis in China (Parenteral, Injection)